AOD-9604

What is AOD-9604?

AOD-9604 is a lab-made fragment of human growth hormone, specifically the tail-end piece (residues 176 to 191) that carries growth hormone's fat-burning activity. It is sold grey-market for fat loss, and more recently for joint repair, and the short version is this: the fat-loss idea is real in animals but failed in people. The pitch makes sense on paper. Growth hormone helps mobilize stored fat, that activity lives in its C-terminus, so a small fragment might copy the fat loss while dropping the rest of the molecule's effects. In rodents that pans out, with oral AOD-9604 cutting body-weight gain by more than half in obese rats, per Heffernan 2000.

From the BioHarmony report, reviewed 2026-09-20.

Safety watch-outs

• Injection-site infection signs (spreading redness, pus, fever): stop and seek care, since the main real risk is contaminated grey-market…
• Any active or suspected cancer: do not use
• any growth-hormone-derived molecule warrants caution without human cancer-safety data.
• Pregnancy or breastfeeding: do not use
• there is no safety data.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for AOD-9604 yet.

Related peptides for recovery & tissue repair

1. 7.5/10BPC-157Strong recommendRecoveryNot FDA approvedBPC-157 is a 15-amino-acid gastric peptide fragment with consistent preclinical repair data, including a 2025 sports-medicine systematic review of 36 studies with 35…
2. 7.5/10TB-500 (Thymosin Beta-4 Fragment)Strong recommendRecoveryNot FDA approvedTB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal…
3. 7.4/10GHK-Cu (Copper Peptide)Strong recommendRecoveryNot FDA approvedGHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
4. 7.3/10Thymosin Alpha-1Strong recommendRecoveryNot FDA approvedFDA identifies immunogenicity and peptide-impurity concerns for compounded thymosin alpha-1 and says available safety information is inadequate.